Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Samotolisib in Japanese patients with advanced malignancies
NCT02536586Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2015
- Primary completion
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of samotolisib in solid tumor (advanced stage), sponsored by Eli Lilly and Company. Primary endpoint: Dose-Limiting Toxicities. Started Sep 2015; status: completed.
02
Drugs
samotolisib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT02536586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02536586.